Article
Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia.
Leukemia - 1 Sept 2012
Stone R M, Fischer T, Paquette R, Schiller G, Schiffer C A, Ehninger G, Cortes J, Kantarjian H M, DeAngelo D J, Huntsman-Labed A, Dutreix C, del Corral A, Giles F
Abstract excerpt
This phase 1b trial investigated several doses and schedules of midostaurin in combination with daunorubicin and cytarabine induction and high-dose cytarabine post-remission therapy in newly diagnosed patients with acute myeloid leukemia (AML). The discontinuation rate on the 50-mg twice-daily do...
Topics
- Adolescent
- Adult
- Age Factors
- Antineoplastic Agents
- Drug Administration Schedule
- Female
- Humans
- Leukemia, Myeloid, Acute
- Male
- Maximum Tolerated Dose
- Middle Aged
- Mutation
- Remission Induction
- Staurosporine